LRCX enters mid-May with an unusual split: analysts are raising targets, the stock is up 10% over the past month, yet short interest has rebuilt sharply over the same window.
Short interest rose 18% in a single week to reach 2.4% of the free float — roughly 30.3 million shares — its highest level in more than a month. The build is notable precisely because it followed a strong post-earnings rally. Shorts added aggressively between May 4 and May 8, even as the stock climbed. The ORTEX short score has ticked up steadily all week, finishing at 33.3, its highest reading in the last ten sessions. Yet the borrow market remains almost completely unencumbered: cost to borrow is just 0.38%, unchanged for weeks, and the lending pool is wide open. Availability is loose by any measure, meaning shorts face no friction entering or covering positions at current levels. Days to cover, per the FINRA fortnightly settlement, is a modest 3.05 days. The short-side pressure is real but not yet a crowded or costly trade.
Options positioning tells a calmer story. The put/call ratio of 1.04 is fractionally below its 20-day average of 1.05, right in line with recent norms and well clear of the 52-week high at 1.37. The z-score of −0.5 signals no unusual demand for downside protection. Given that the next earnings event is not until July 30, options traders appear content to sit on the sidelines for now.
The Street is broadly constructive. JPMorgan raised its target to $315 from $300 after the April 22 print, maintaining Overweight. TD Cowen took the most aggressive step, lifting to $340 from $290 while holding Buy. RBC, Citi, Wells Fargo, and Stifel all moved targets higher — most landing in the $310–$325 range — reflecting consensus that the earnings report cleared the bar. The sole dissenter in tone, Barclays, raised its Equal-Weight target to $275 from $255, keeping a more cautious stance. The mean price target across 25 buys is $310, roughly 7% above the current $289 close. Seaport Global initiated fresh coverage at Buy with a $300 target on May 5. The analyst-recommendation differential ranks in the 87th percentile, meaning very few sell-side voices are in the bear camp. The bull case centres on Lam's dominant position in etch and deposition, strength in advanced packaging, and a memory capex cycle that is turning. The bear case focuses on customer concentration — the top four account for a disproportionate share of revenues — and export-control exposure, a risk that has not faded.
Valuation has compressed modestly on a trailing basis. The EV/EBITDA multiple slipped to 36.7x, down more than 5 turns over 30 days, and the trailing P/E of 44.6x fell about 1.4 points over the same period. Both moves reflect the stock re-rating alongside earnings rather than a deterioration in the underlying business. The RSI sits at 62, leaving room before technically overbought territory.
On the institutional side, BlackRock added more than 10 million shares in the period to April 30, lifting its stake to 10.7% of shares outstanding. FMR (Fidelity) added 3.7 million shares over the same window. T. Rowe Price's reported addition of 10.7 million shares is the largest disclosed increment among the major holders, though the filing period extends to March 31. The institutional picture is broadly accumulative. Against that backdrop, insider activity runs the other direction: the CFO, CTO, and CLO all sold shares in February and March at prices in the $222–$234 range, well below the current level, and a Senior VP sold 18,170 shares on May 1 at $255. Net insider sales over 90 days total roughly $110 million. These appear to be programmatic or plan-based rather than conviction calls, given the timing and the low trade-significance scores attached to each.
Among correlated peers, AMAT and KLAC posted near-identical weekly gains of around 5%, keeping the semiconductor equipment group broadly in step. ACMR and MU outperformed sharply, each up roughly 19–20% on the week. CAMT is the outlier, down 11% on the week and nearly 16% in a single session — a reminder that single-name risk within the equipment complex remains elevated. LRCX's relative steadiness through this divergence suggests the market sees it as a core holding rather than a tactical bet.
With Q3 results not due until July 30, the coming weeks are less about catalysts and more about whether the short rebuild — concentrated in just four trading sessions — stabilises or continues to build pressure against a stock trading below the consensus target.
See the live data behind this article on ORTEX.
Open LRCX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
